Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Seongnam-si, Gyeonggi-do, Korea, Republic of Clinical Trials

A listing of Seongnam-si, Gyeonggi-do, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (14) clinical trials

Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors

This is a Phase Ib, open label, multicenter dose escalation study designed to assess the safety, tolerability, and pharmacokinetics of oral dosing of cobimetinib and HM95573 administered in combination in patients with histologically/cytologically confirmed, locally advanced, or metastatic solid tumors with RAS- or RAF-mutation for which standard therapies either do ...

Phase

0.0 miles

Learn More »

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

This is a Phase I, open-label, dose-escalation trial with consecutive parallel-group expansion in selected solid tumor indications. The current trial is composed of a standard dose escalation "3 + 3" cohort design, for which 3 to 6 subjects will be enrolled at each dose level depending on the occurrence of ...

Phase

0.0 miles

Learn More »

A Dose Escalation Study Of PF-06801591 In Melanoma Head And Neck Cancer (SCCHN) Ovarian Sarcoma Non-Small Cell Lung Cancer Urothelial Carcinoma or Other Solid Tumors

Protocol B8011001 is a Phase 1, two part, open-label, multi center, multiple-dose, safety, efficacy, PK, and PD study of PF-06801591 administered intravenously (IV) or subcutaneous (SC) in previously treated adult patients with locally advanced or metastatic melanoma, squamous cell carcinoma head and neck (SCCHN), ovarian carcinoma, sarcoma, non-small cell lung ...

Phase

0.0 miles

Learn More »

A Dose Escalation Study of JNJ-61186372 in Participants With Advanced Non-Small Cell Lung Cancer

This open label (all participants know the identity of the study drug), multicenter (more than one study site), first-in-human study consists of 2 parts. Part 1 is a dose escalation and Part 2 is a dose expansion cohort. In Part 1, participants with evaluable non-small cell lung cancer (NSCLC) will ...

Phase

0.0 miles

Learn More »

Safety Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).

This is a study to evaluate safety, tolerability and PK of DKF-310 IM injection in healthy male volunteers.

Phase

0.0 miles

Learn More »

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

This is a Phase Ib, open-label, multicentre study of AZD9291 administered orally in combination with novel therapeutics (AZD6094 or selumetinib (AZD6244, ARRY142886)) to patients with EGFRm+ advanced NSCLC. The study has been designed to allow an investigation of the optimal combination dose and schedule whilst ensuring the safety of patients ...

Phase

0.0 miles

Learn More »

A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma

This phase 1 clinical study (AT148001) is an open-label, multi-center, multiple-dose, dose-escalation, safety, PK, and PD study of ALX148. The phase 1 protocol will have 2 parts: a single agent dose escalation phase (Part 1) and a combination therapy phase (Part 2). Part 2 will include an initial dose escalation ...

Phase

0.0 miles

Learn More »

KM-819 for Patients With Parkinson's Disease

This first in human, single-center, randomized, placebo-controlled, double blind, sequential group Phase 1 study in healthy subjects will be conducted to evaluate the safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) following the escalation of single and multiple doses of KM-819. The study will consist of 2 parts. In Part A, ...

Phase

0.0 miles

Learn More »

Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF KRAS or NRAS Mutant Solid Cancers

This study evaluates the anti-tumor efficacy and safety of single agent HM95573 administered in patients with solid tumors harboring mutations in either BRAF, KRAS or NRAS gene.

Phase

0.0 miles

Learn More »

Clinical Trial Phase I for Theragene in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer

Pancreatic cancer is associated with an extremely poor prognosis, reflected by a 5-y survival probability of less than 5% when all stages are combined. At present, only approximately 10%-20% of patients are considered candidates for curative resection. The majority of patients (50%-60%) are present with metastatic disease, and substantial number ...

Phase

0.0 miles

Learn More »